ACADIA Pharmaceuticals

NASDAQ ACAD
$25.26 -0.24 -0.94%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 42.5 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
2.78B
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
2.58B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.38
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
167.67M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
37.66 %

Upcoming events ACADIA Pharmaceuticals

All events
No upcoming events scheduled

Stock chart ACADIA Pharmaceuticals

Stock analysis ACADIA Pharmaceuticals

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
12.17 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
4.17 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
8.63 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-0.69 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
29.91 -50.00

Price change ACADIA Pharmaceuticals per year

14.10$ 26.57$
Min Max

Summary analysis ACADIA Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure ACADIA Pharmaceuticals

Revenue and net income ACADIA Pharmaceuticals

All parameters

About company ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Address:
12830 El Camino Real, San Diego, CA, United States, 92130
Company name: ACADIA Pharmaceuticals
Issuer ticker: ACAD
ISIN: US0042251084
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2004-05-27
Sector: Healthcare
Industry: Biotechnology
Site: https://www.acadia-pharm.com